Clinical trials: Atopic Hypersensitivity
Atopic Dermatitis
POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections.
- Trial name
- ADAMANT (NCT05932654)
- Testing
- BSI-045B
- Where
- 17 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biosion, Inc.
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD7 (NCT03733301)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 68 sites in Argentina, Australia and 8 more
- Volunteers
- 329 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream, twice-daily, for 28 days in otherwise healthy adult…
- Trial name
- NCT02655679
- Testing
- VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
- Where
- 12 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Vitae Pharmaceuticals, Inc.
Healthy, Atopic Dermatitis
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants.
- Trial name
- NCT06119529
- Testing
- LY3872386, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT03443024
- Testing
- Lebrikizumab
- Where
- 58 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Contact
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability…
- Trial name
- NCT00929981
- Testing
- Tablet Methylprednisolone (4 or 16 mg)
- Where
- 4 sites in India
- Volunteers
- 80 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and…
- Trial name
- NCT04668066
- Testing
- PF-07242813
- Where
- 7 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT03568331
- Testing
- Tradipitant
- Where
- 70 sites in United States
- Volunteers
- 375 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis Eczema, Atopic Dermatitis
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
This is a pragmatic, randomized, controlled, equivalency trial. This 12-month trial will evaluate the impact of an online, team-based connected health (TCH) model for management of atopic dermatitis (AD) as compared to in-person…
- Conditions
- Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
- Trial name
- TCH in AD (NCT03981926)
- Testing
- Team-Based Connected Health (TCH)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Southern California
Atopic Dermatitis
A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects
To assess the safety (especially skin findings) and pharmacokinetics by applying 0.3%, 1%, or 3% formulation of 5g OPA-15406 ointment to a 1000 cm2 area as a single-dose and as a multiple-dose twice daily for 2 weeks in Japanese…
- Trial name
- NCT02334787
- Testing
- 0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 3% OPA-15406 Ointment
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
This was a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12 and ≤ 48 (0-72 scale).
- Trial name
- NCT02424253
- Testing
- ZPL-3893787
- Where
- 17 sites in Belgium, Germany and 2 more
- Volunteers
- 98 people
- Sponsor
- Ziarco Pharma Ltd
Atopic Dermatitis (AD)
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
To investigate the efficacy of 0.3% OPA-15406 ointment when administered twice daily for 4 weeks in infants younger than 2 years of age with Atopic Dermatitis
- Trial name
- NCT05372653
- Testing
- OPA-15406
- Where
- Japan
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
The purpose of this randomized, double blind, placebo controlled, parallel group study is to compare the safety and efficacy of topically applied DS107 cream (1% and 5%) versus vehicle cream, in the treatment of adult patients…
- Trial name
- NCT02925793
- Testing
- DS107, Vehicle cream
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 327 people
- Sponsor
- DS Biopharma
Atopic Dermatitis
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01548404
- Testing
- Dupilumab
- Where
- 21 sites in Czechia, France and 3 more
- Volunteers
- 109 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis.
- Trial name
- NCT06280716
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 46 sites in China, South Korea
- Volunteers
- 301 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and…
- Trial name
- TRuE-AD4 (NCT06238817)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 241 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
- Trial name
- NCT05014568
- Testing
- tapinarof cream, 1%, Vehicle cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 407 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo on change from baseline in Total Lesion Symptom Score in subjects with mild to…
- Trial name
- KINSHIP (NCT02324972)
- Testing
- AQX-1125
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Asthma
Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
In patients with asthma, reactions to allergens in the environment (such as mold, pollen, weed, domestic pets, and dust allergens) play an important role in causing asthma symptoms.
- Trial name
- NCT02111772
- Testing
- Rhinovirus
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Virginia